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Abstract
Background: Hemodialysis patients are at risk for deficiency of essential trace elements and
excess of toxic trace elements, both of which can affect health. We conducted a systematic review
to summarize existing literature on trace element status in hemodialysis patients.
Methods: All studies which reported relevant data for chronic hemodialysis patients and a healthy
control population were eligible, regardless of language or publication status. We included studies
which measured at least one of the following elements in whole blood, serum, or plasma: antimony,
arsenic, boron, cadmium, chromium, cobalt, copper, fluorine, iodine, lead, manganese, mercury,
molybdenum, nickel, selenium, tellurium, thallium, vanadium, and zinc. We calculated differences
between hemodialysis patients and controls using the differences in mean trace element level,
divided by the pooled standard deviation.
Results:  We identified 128 eligible studies. Available data suggested that levels of cadmium,
chromium, copper, lead, and vanadium were higher and that levels of selenium, zinc and manganese
were lower in hemodialysis patients, compared with controls. Pooled standard mean differences
exceeded 0.8 standard deviation units (a large difference) higher than controls for cadmium,
chromium, vanadium, and lower than controls for selenium, zinc, and manganese. No studies
reported data on antimony, iodine, tellurium, and thallium concentrations.
Conclusion: Average blood levels of biologically important trace elements were substantially
different in hemodialysis patients, compared with healthy controls. Since both deficiency and excess
of trace elements are potentially harmful yet amenable to therapy, the hypothesis that trace
element status influences the risk of adverse clinical outcomes is worthy of investigation.
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Background
Hemodialysis is the most common form of treatment for
end-stage renal disease (ESRD), and is associated with
considerable morbidity and mortality due to accelerated
cardiovascular disease and infection. Despite the well-
documented burden of disease, much remains to be
learned about how best to prevent these complications of
hemodialysis.
Hemodialysis removes uremic toxins primarily by allow-
ing equilibration of plasma and dialysate across a semi-
permeable membrane. Dialysate is created by adding care-
fully regulated quantities of biologically essential ions
such as potassium, sodium, bicarbonate, and calcium to
water that has been treated to reduce solutes to very low
levels. The dialysate concentration of other substances
such as trace elements is not routinely manipulated. Sub-
stances that have lower concentrations in dialysate than in
blood tend to be removed by dialysis. Although this is
appropriate in the case of uremic toxins, it may lead to
depletion of biologically essential substances. Besides the
potential for ongoing removal of trace elements by dialy-
sis, hemodialysis patients are at risk for low dietary intake
of such substances due to uremia-related anorexia and
dietary restrictions.
Hemodialysis patients are exposed to very high volumes
(>300 liters/week) of dialysate. Therefore, even minute
levels of toxic substances in source water could lead to tiny
concentration gradients between blood and dialysate,
which in turn could lead to clinically relevant toxicity.
Substances present in dialysate but not in blood will tend
to accumulate in the patient, and the lack of renal clear-
ance in hemodialysis patients might theoretically lead to
toxicity of ingested trace elements even when they are not
present in dialysate. Thus, hemodialysis patients are at
theoretical risk for both deficiency and accumulation of
trace elements, depending on dietary intake, removal by
dialysis, the composition of the source water used for
hemodialysis, and residual kidney function [1-3].
Deficiency of essential trace elements (such as zinc or sele-
nium) and excess of potentially harmful trace elements
(such as lead or arsenic) are both known to have adverse
consequences in the general population [4-10]. Although
not established, it is plausible that disordered trace ele-
ment nutritional status (if present) would contribute to
morbidity and mortality among hemodialysis patients as
well. However, the incidence of abnormal trace element
status in dialysis patients has not been comprehensively
studied. We performed a systematic review to compare
trace element status between hemodialysis patients and
healthy controls.
Methods
Data sources and searches
This systematic review is reported according to published
guidelines [11]. An expert librarian conducted a compre-
hensive search to identify all relevant studies regardless of
language or publication status. Three electronic databases,
MEDLINE (1966 to 13 April 2008), EMBASE (1988 to 13
April 2008), and the Cochrane Library (13 April 2008)
were searched. The detailed search strategies are included
in Additional file 1. A subject specialist and a methodolo-
gist screened each citation or abstract. Any study consid-
ered potentially relevant by at least one reviewer was
retrieved for further review.
Study selection
The full text of each potentially relevant study was inde-
pendently assessed by two reviewers for inclusion in the
review using predetermined eligibility criteria on a pre-
printed form. Studies were eligible for inclusion if they
measured trace element concentrations in both a chronic
hemodialysis population and a healthy control popula-
tion. We selected the following trace elements for study a
priori  based on their known or suspected potential to
influence health, and after consideration of existing stand-
ards for hemodialysis water quality [12]: antimony,
arsenic, boron, cadmium, chromium, cobalt, copper, flu-
orine, iodine, lead, manganese, mercury, molybdenum,
nickel, selenium, tellurium, thallium, vanadium, and
zinc. Only studies that measured trace element status in
whole blood, serum, or plasma were included. Disagree-
ments were resolved by discussion and consultation with
a third party. Disagreements arose with 6% of the articles
(κ = 0.88).
Data extraction and quality assessment
We assessed and reported the study quality of included
studies using the Downs and Black checklist [13]. Two
reviewers independently assessed each included study,
and resolved disagreements with the aid of a third party
through consensus. An average of 18% of disagreements
on quality items occurred. Study characteristics and data
of interest were pre-specified, and were recorded in a pur-
pose-built database. One reviewer extracted the data. A
second reviewer checked the data for accuracy.
Data synthesis and analysis
We analyzed data using Review Manager 4.2.10 (Oxford,
UK) and Stata 10.0 (College Station, Texas, USA). We cal-
culated standardized mean differences (SMD) [14]; the
hemodialysis population mean minus the control popu-
lation mean divided by their pooled standard deviation
(SD). By presenting the differences in means relative to
variability, we removed the heterogeneous effects of bothBMC Medicine 2009, 7:25 http://www.biomedcentral.com/1741-7015/7/25
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unit and assay, with SMD of 0.2, 0.5, and 0.8 units of SD
representing small, medium, and large sizes of effect,
respectively [15]. One study [16] reported geometric
means rather than arithmetic means, requiring us to
standardize the differences in log means rather than the
differences in mean [17].
We assessed heterogeneity using the I2 statistic [18,19],
and found considerable between-study heterogeneity (I2
>85%). Therefore, the primary method of pooling data
across studies used a qualitative approach (vote counting
[20]; used to tally the number of studies finding that the
level of a particular trace element was lower or higher in
hemodialysis patients than in controls). We used the sign
test to determine whether the vote count tally was statisti-
cally significant (provided that there were at least three
studies which reported results for the element in ques-
tion). To provide guidance on the relative magnitude of
the differences between hemodialysis patients and con-
trols, we also report random-effects estimates of the
pooled SMD for elements where the sign test indicated
that levels were significantly different between these two
populations. Given the presence of large heterogeneity,
we did not formally assess for the presence of publication
bias [21].
Statistical sources of heterogeneity were explored using
weighted least squares meta-regression [22]. The follow-
ing study-level variables were considered: sample source
(whole blood, serum, plasma), mean duration of hemo-
dialysis treatment (in months), continent on which the
study was performed (Americas/Europe versus other) and
measurement technique (absorption spectroscopy versus
other). The effect of sample size was also explored given
the tendency for SDs to be underestimated [23], and
therefore SMDs overestimated, when sample sizes are
small (N <30).
Results
Search yield
From 1,481 identified citations and abstracts, 226 full
articles were retrieved for detailed evaluation (Figure 1).
Of these, 128 studies [2,16,24-149] reported relevant data
and were included in this review. Most studies were con-
ducted in Europe (47%), Asia (30%), and North America
(14%). Seventy-four percent of data came from cross-sec-
tional studies; the remaining data from baseline assess-
ments of randomized controlled trials and prospective
cohort studies. Most studies used absorption spectros-
copy, emission spectroscopy or neutron activation to
measure trace element levels in biological specimens
(Additional file 2). Multiple variants of absorption spec-
troscopy were used.
Populations studied
Sample sizes of hemodialysis patients ranged from 6 to
456 (median 24; Additional file 2). Mean ages ranged
from 32 to 74 and percent male ranged from 0% to 100%.
Little information was reported on the primary cause of
ESRD, co-morbidities, or membrane properties. Control
group sample sizes ranged from 5 to 490 (median 28).
Mean ages ranged from 28 to 74 and percent male ranged
from 0% to 100%. Hospital or laboratory staff (13%),
blood donors (7%), non-renal patients (6%), or people
drawn from the general population in the same geo-
graphic region (6%) were the most commonly specified
source populations for control groups. Results of quality
assessment are reported in Additional file 2. Time spent
on dialysis (39%), description of control participants
(29%), and eligibility criteria (20%) were poorly
reported. Adjustment or matching for age and sex was
infrequent (20%). Technique was well reported (98%),
but consideration for measurement error was poor (34%).
Trace element status
Data were available for arsenic, boron, cadmium, chro-
mium, cobalt, copper, fluorine, lead manganese, mercury,
molybdenum, nickel, selenium, vanadium, and zinc. The
pooled results comparing trace element status for hemo-
dialysis patients with controls are presented in Table 1
and Figure 2. Results stratified by sample source (whole
blood, serum, or plasma), or repeated using a fixed-effect
model were consistent (data not shown). Available data
suggested that levels of cadmium, chromium, copper,
lead, and vanadium were higher and that levels of manga-
nese, selenium, and zinc were lower in hemodialysis
patients, compared with controls (Table 2). The magni-
tude of these differences was large (>0.8 SD units) for cad-
mium, chromium, vanadium, selenium, zinc, and
manganese.
Available data for arsenic, boron, cobalt, fluorine, mer-
cury, molybdenum, and nickel were either too limited or
too heterogeneous to report. No studies reported data on
antimony, fluorine, iodine, tellurium, and thallium.
Meta-regression
We attempted to identify potential explanations for the
observed between-study heterogeneity using meta-regres-
sion. None of the characteristics considered (sample
source, duration of hemodialysis treatment, continent on
which the study was performed, or measurement tech-
nique) significantly modified the association between
hemodialysis treatment and the blood levels of the trace
elements studied (data not shown).BMC Medicine 2009, 7:25 http://www.biomedcentral.com/1741-7015/7/25
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Discussion
We found that hemodialysis patients appear to have lower
levels of zinc and selenium than people in the general
population. Zinc deficiency is a leading cause of disease in
developing countries [4], and is associated with delayed
wound healing [5], and immune deficiency characterized
by impaired cell proliferation, abnormal T-cell function,
defective phagocytosis, and abnormal cytokine expression
[150,151], all of which might contribute to the excess risk
of infection observed in hemodialysis patients [152-157].
Zinc deficiency may also cause or contribute to a number
of relatively non-specific conditions commonly observed
Flow diagram of study selection Figure 1
Flow diagram of study selection.BMC Medicine 2009, 7:25 http://www.biomedcentral.com/1741-7015/7/25
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in hemodialysis patients, including anorexia [158], dys-
geusia [159], and impaired cognitive function [160].
Although the biological significance of low blood sele-
nium concentrations is less clear, severe selenium defi-
ciency leads to sudden death and cardiomyopathy in the
general population [6,7,161]. Lower levels of serum sele-
nium without severe deficiency have been associated with
hypertension [162], heart failure [163,164], and coronary
disease [165] in the general population, and with cardio-
myopathy among dialysis patients [1,166,167]. Finally,
mild selenium deficiency appears to increase susceptibil-
ity to oxidant stress [168,169], which may be relevant to
hemodialysis patients in whom oxidative stress is mark-
edly increased [170-172].
In addition to the lower levels of selenium and zinc,
hemodialysis patients seem to have higher average levels
of certain trace elements compared with healthy controls.
It was not possible to compare absolute levels of trace ele-
ments across studies (given the different techniques and
specimens), and therefore we could not estimate the pro-
portion of hemodialysis patients who have trace element
levels in the toxic range. However, for many of the ele-
ments, the SMD for the differences between hemodialysis
patients and controls exceeded 0.8 SD, which is consid-
ered to be a large between-group effect by authorities [15].
For most of the trace elements studied, the biological sig-
nificance of higher blood levels is unclear. However,
excessive levels of lead or arsenic in blood and other tis-
sues are known to be potentially harmful. For example,
minor elevations in whole blood lead levels are associated
with impaired cognitive function [173,174], impaired
hemoglobin synthesis, and hypertension [175,176]. Cere-
brovascular disease and renal insufficiency [177-179] also
appear to be more frequent at higher levels of blood lead,
perhaps mediated by higher blood pressure. Thus, higher
blood levels of lead may increase the risk of cardiovascular
disease, although the mechanism remains unclear. Simi-
larly, inorganic arsenic causes tissue damage by multiple
mechanisms including oxidative injury [180,181], inhibi-
tion of DNA repair [182], and chromosomal damage
(deletion, aneuploidy [183]), and higher levels of arsenic
are associated with increased risk of peripheral vascular
disease [184,185]. Animal studies suggest that low sele-
nium status may predispose to arsenic toxicity [186], and
underweight or malnourished humans may also be at
increased risk [187], suggesting that hemodialysis patients
may be at higher than average risk of arsenic toxicity.
Implications of the findings
Although the concentration of some trace elements in
hemodialysis source water is monitored annually in
accordance with federal regulation [188], blood or body
levels of these substances are rarely (if ever) measured in
hemodialysis patients. The potential for the accumulation
of trace elements to cause harm in hemodialysis patients
is exemplified by aluminum. Aluminum toxicity led to
serious toxicity (anemia, disabling encephalopathy, neu-
ropathy and severe symptomatic bone disease) in dialysis
patients prior to the recognition that aluminum in dia-
lysate and oral medications was responsible [189-193]. It
is difficult to overstate the importance of this discovery for
nephrology practice, which led to the elimination of alu-
minum-related toxicity (and substantial improvements in
patient outcomes) within a few years. Today, clinically
obvious toxicity due to accumulation of aluminum is
exceedingly rare in hemodialysis patients, and the existing
regulation [188] has been remarkably effective at reducing
the risk of acute toxicity from excess trace elements such as
fluorine [194-196]. However, the possibility that other
trace elements may accumulate in patients with kidney
failure and cause unrecognized chronic toxicity has
received surprisingly little attention.
Oral trace element supplements are readily available, and
oral zinc and selenium preparations have been shown to
Standardized mean differences of trace element concentra- tions: hemodialysis participants versus healthy controls Figure 2
Standardized mean differences of trace element con-
centrations: hemodialysis participants versus healthy 
controls. The small solid gray diamonds represent the 
standardized mean difference (SMD) in trace element con-
centrations between hemodialysis patients and controls (for 
each individual study). The large red crosses represent the 
random-effects pooled SMDs. Results were pooled only for 
trace elements that were measured in at least three studies 
and for which the sign test was statistically significant. The 
shaded gray region denotes SMD representing differences 
between hemodialysis patients and controls, which are mod-
erate or small (<0.8 standard deviation). Data points outside 
the gray region represent large differences between hemodi-
alysis patients and controls (SMD ≥0.8 standard deviation).BMC Medicine 2009, 7:25 http://www.biomedcentral.com/1741-7015/7/25
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Table 1: Trace element concentrations independent of sample source
Element Number
of
cohortsb
Number of
hemodialysis
participants
and control
participants
Pooleda 
SMD
I2, 
%
Range of 
SMDs
Number of 
studies
significantly
favouring
lower
concentrations
in hemodialysis
participants
Number of 
studies
significantly
favouring lower
concentrations
in control
participants
Number of
studies with
non-significant
findings
Arsenic 3 110/54 - 96 (-1.23, 1.77) 1 1 1
Boron 4 69/494 - 96 (-5.21, 2.96) 1 1 2
Cadmium 6 722/968 2.07 98 (-1.01, 7.7) 1 5c 0
Chromium 11 330/635 0.84 95 (-0.66, 5.14) 0 6c 5
Cobalt 1 7/9 - - - 0 0 1
Copper 42 1712/1444 0.52 93 (-1.74, 5.28) 6 16c 20
Fluorine 1 7/8 - - - 0 1 0
Lead 14 1217/1751 0.11 96 (-2.89, 1.73) 4 5c 5
Manganese 8 399/522 -0.7 96 (-3.96, 0.29) 4c 04
Mercury 2 607/264 - 99 (-0.94, 0.49) 1 1 0
Molybdenum 1 14/59 - - - 0 1 0
Nickel 9 369/323 - 99 (-3.96, 4.67) 3 6 0
Selenium 46 1496/1443 -1.50 91 (-9.16, 1.97) 37c 18
Vanadium 5 112/137 3.07 87 (1.18, 6.28) 0 5c 0
Zinc 74 2515/2699 -1.61 95 (-8.99, 3.24) 56c 51 3
aPooled SMDs using the random-effects method; this estimate indicates the average effect of all included studies. Negative values indicate lower 
concentrations in the hemodialysis participants and positive values indicate lower concentrations in the control participants. Pooled SMDs are 
reported only when vote counting results are significant.
bSome studies counted more than once if results reported by strata, for example, women and men separately.
cVote counting sign test results were significant at the P ≤ 0.05 level. Applied to comparisons with a minimum of three studies.
SMD = standardized mean difference.
Table 2: Summary of findings
Probably accumulates in 
hemodialysis patients
May accumulate in hemodialysis 
patients
Probably deficient in hemodialysis 
patients
Insufficient information
Cadmium X
Chromium X
Nickel X
Vanadium X
Copper X
Lead X
Manganese X
Selenium X
Zinc X
Antimony X
Arsenic X
Boron X
Cobalt X
Fluorine X
Iodine X
Mercury X
Molybdenum X
Tellurium X
Thallium XBMC Medicine 2009, 7:25 http://www.biomedcentral.com/1741-7015/7/25
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increase blood levels of these elements in dialysis patients
[197-200]. However, few data describe the impact of trace
element supplementation on clinical outcomes in hemo-
dialysis patients, despite the fact that correction of zinc
deficiency is beneficial in the general population [5,201-
204], including significantly reducing the risk of infection
and all-cause death [205-211]. Data examining the rela-
tion between trace element status and clinical outcomes
in hemodialysis patients are similarly scarce. One rela-
tively small (N = 265) study published in the Lithuanian
language shows a significant association between lower
plasma zinc levels and the risk of infection [212]. Our
data suggest that future studies should investigate the link
between zinc or selenium status and clinical outcomes in
dialysis patients, in whom the risk of infection is dramat-
ically elevated compared with people with normal kidney
function [152-157].
Limitations
The available literature has several potentially important
limitations. First, study quality was moderate to poor, and
many of the studies were relatively small. Second, the
available data include multiple different analytical tech-
niques, study populations, control groups, and specimen
types (whole blood, serum, plasma). Perhaps for this rea-
son, there was substantial between-study heterogeneity in
the results, meaning that the extent to which trace element
levels are higher or lower in hemodialysis patients cannot
be estimated with certainty. We were unable to identify
statistical sources of this heterogeneity, perhaps because
we only had access to study-level (rather than patient-
level) data. Despite the heterogeneity, for several of the
elements studied, the great majority of studies found dif-
ferences between hemodialysis patients and controls.
Since the same technique and specimen types were used
for both patients and controls, it is unlikely that these dif-
ferences are spurious. However, it remains possible that
important differences exist for other substances known or
suspected to influence health. Third, studies generally did
not report data on dietary intake of trace elements and
thus we cannot assess whether reduced consumption of
foods containing zinc and selenium was responsible for
the lower levels of these elements among hemodialysis
patients. Fourth, although we found large differences
between the blood levels of certain trace elements in
hemodialysis patients and those in control participants,
the clinical significance of this finding remains to be con-
firmed. Fifth, although we studied blood levels of trace
elements, it is possible that bone or other compartments
may better reflect trace element body status, especially for
heavy metals such as lead [213]. Sixth, although simulta-
neous derangement of multiple trace elements (for exam-
ple, low selenium and excess arsenic) may have synergistic
toxicity [186], the nature of the available data precluded
us from determining how frequently this occurs in hemo-
dialysis patients. Finally, although all systematic reviews
have potential limitations, we conducted and reported
this analysis according to published guidelines aimed at
reducing bias [11]. Nonetheless, as with all systematic
reviews, the strength of our conclusions is influenced by
the quality of the studies on which they are based.
Conclusion
In summary, we found that average blood concentrations
of biologically important trace elements were substan-
tially different in hemodialysis patients, compared with
healthy controls. Since both deficiency and excess of trace
elements are potentially amenable to therapy, the hypoth-
esis that trace element status influences the risk of adverse
clinical outcomes appears worthy of investigation, espe-
cially when one considers the experience of the nephrol-
ogy community with aluminum.
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